IGF-1 LR3 1mg + CJC-1295 (without DAC) 10mg +Ipamorelin 10mg

The GH-IGF-1 Axis Research Complex covers three intervention points across the GH-IGF-1 axis in a single bundle: CJC-1295 Without DAC (upstream GHRHR activation), Ipamorelin (parallel GHSR-1a activation), and IGF-1 LR3 (downstream IGF-1 receptor signalling). CJC-1295 and Ipamorelin stimulate GH secretion through mechanistically distinct pituitary receptors, while IGF-1 LR3 — a modified 83-amino acid IGF-1 analogue with extended in-vitro half-life due to reduced IGFBP binding — allows researchers to study the downstream growth factor component of the axis in isolation from upstream GH secretion.

This three-compound design is suited to research programmes investigating the complete GH-IGF-1 signalling cascade, from upstream secretagogue activity through to downstream receptor engagement, within a single experimental system.

Every compound in the GH-IGF-1 Axis Research Complex is independently tested by Janoshik laboratory. HPLC purity is confirmed at ≥98% on all three compounds, with LC-MS molecular identity verification. Batch-specific Certificates of Analysis are publicly accessible for IGF-1 LR3, CJC-1295, and Ipamorelin before purchase.

For laboratory handling purposes, CJC-1295 and Ipamorelin may be reconstituted using BP-grade bacteriostatic water; IGF-1 LR3 may be reconstituted using dilute acetic acid or another suitable buffer. Store all three at -20°C, avoiding repeated freeze-thaw cycles.

For complete mechanism detail on each compound, see the IGF-1 LR3, CJC-1295, and Ipamorelin research guides on the Ascend Peptides UK blog, or the GH axis research peptides category page.